Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48‐month longitudinal cohort study
KB Sims(Massachusetts General Hospital), Daniel I. Rosenthal(Harvard University), Seymour Packman(University of California, San Francisco), NJ Weinreb(University Research Co (United States)), Ramnik J. Xavier(Massachusetts General Hospital), MA Fitzpatrick(SynZyme Technologies (United States)), Paige Kaplan(Children's Hospital of Philadelphia), BE Rosenbloom(Tower Cancer Research Foundation), Jennifer Angell, Henry J. Mankin(Harvard University), J. A. Barranger(University of Pittsburgh), GM Pastores(New York University)
Cited by 134
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Defining trained immunity and its role in health and disease
|Nature reviews. Immunology|2020|2.5k